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De novo SCN1A mutations in Dravet syndrome
and related epileptic encephalopathies are largely
of paternal origin
Sarah E Heron,1,2 Ingrid E Scheffer,3,4 Xenia Iona,1 Sameer M Zuberi,5 Rachael Birch,6
Jacinta M McMahon,3 Carla M Bruce,3 Samuel F Berkovic,3 John C Mulley1,2,7
ABSTRACT
Background Dravet syndrome is a severe infantile
epileptic encephalopathy caused in approximately 80% of
cases by mutations in the voltage gated sodium channel
subunit gene SCN1A. The majority of these mutations are
de novo. The parental origin of de novo mutations varies
widely among genetic disorders and the aim of this study
was to determine this for Dravet syndrome.
Methods 91 patients with de novo SCN1A mutations
and their parents were genotyped for single nucleotide
polymorphisms (SNPs) in the region surrounding their
mutation. Allele specific polymerase chain reaction (PCR)
based on informative SNPs was used to separately
amplify and sequence the paternal and maternal alleles to
determine in which parental chromosome the mutation
arose.
Results The parental origin of SCN1A mutations was
established in 44 patients for whom both parents were
available and SNPs were informative. The mutations were
of paternal origin in 33 cases and of maternal origin in the
remaining 11 cases. De novo mutation of SCN1A most
commonly, but not exclusively, originates from the
paternal chromosome. The average age of parents
originating mutations did not differ from that of the
general population.
Conclusions The greater frequency of paternally derived
mutations in SCN1A is likely to be due to the greater
chance of mutational events during the increased number
of mitoses which occur during spermatogenesis
compared to oogenesis, and the greater susceptibility to
mutagenesis of the methylated DNA characteristic of
sperm cells.
INTRODUCTION
Dravet syndrome (DS), or severe myoclonic
epilepsy of infancy (SMEI) (OMIM #607208) is a
severe epileptic encephalopathy with onset around
6 months of age. Patients typically present with
febrile hemiclonic or generalised tonic-clonic status
epilepticus, followed by the development of other
seizure types including myoclonic, focal, absence
and atonic seizures between 1e4 years. Develop-
ment is normal in the ﬁrst year of life with subse-
quent developmental slowing and sometimes
regression. Cognitive outcome is poor with ongoing
refractory seizures; ataxia and spasticity may
evolve.1 Some patients who lack one or more of the
clinical features have been regarded as having the
borderland variant of SMEI (SMEB). Recent work
led to the suggestion that both the classical and the
borderland variants of SMEI be incorporated under
the eponym of DS as they share clinical features and
may be caused by the same mutations.2 3
The majority of cases of DS are caused by de
novo loss of function mutations in the voltage
gated sodium channel a1 subunit gene SCN1A
(OMIM *1823890).3e6 Approximately 80% of
patients with DS have point mutations or small
insertions or deletions in the SCN1A gene.3 Large
deletions affecting one or more exons or the entire
gene and adjacent sequences are also seen in a small
proportion of cases.6e9 Similar SCN1A mutations
may also cause other infantile epileptic encephalo-
pathies including severe infantile multifocal
epilepsy, cryptogenic generalised epilepsy and, in a
few patients, myoclonic astatic epilepsy.3 6 10
The parental origin of mutations has been
studied for a number of disorders caused by de
novo mutations, including various forms of
craniosynostosis,11e13 achondroplasia,14 Rett
syndrome,15 16 haemophilia A,17 neuroﬁbromatosis
I18 and neonatal diabetes.19 Data from many of
these studies has been collated in the imprinted
gene and parent-of-origin effect database (http://
www.otago.ac.nz/IGC).20 In almost all of the
diseases studied, there is a bias towards paternal
origin of the de novo mutations, with between
65e100% of mutations arising on the paternal
chromosome. Exceptions are von HippeleLindau
disease,21 tuberous sclerosis22 and haemophilia B,23 24
where mutations originate with approximately
equal frequency on the paternal and maternal
alleles.
The aim of this study was to determine the
parent-of-origin of de novo SCN1A mutations in
patients with DS and other infantile encephalo-
pathies, and to determine whether there is any
relationship between parental age, mutagenesis in
SCN1A, and the occurrence of DS and related
disorders.
METHODS
Patients and mutation screening
Patients with DS or other epileptic encephalo-
pathies with de novo SCN1A mutations were
included if DNA was available from one or both
parents. Ninety-one patients were studied, 84 of
whom have been described elsewhere.3 8 25 26 The
study was approved by the human research ethics
committees of Austin Health and the Women’s and
Children’s Hospital.
Patients were screened for mutations in SCN1A
as previously described.3 25 Where available, the
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parents were sequenced for the mutation in the amplicon in
which the mutation was detected in their child.
Single nucleotide polymorphism identification and genotyping
The region surrounding the mutation was polymerase chain
reaction (PCR) ampliﬁed and sequenced for each patient and his
or her parents to genotype any single nucleotide polymorphism
(SNPs) that were present. The primer sequences used for
ampliﬁcation are listed in supplementary table 1. Additional
internal primers were used for sequencing; these were the
primers used previously for SCN1A mutation screening.10
Genotyping was done for certain SNPs using restriction enzyme
digestion. The primer sequences and restriction enzymes used for
these assays are listed in supplementary table 2.
Genotyping was done for one SNP, rs13060006, by high
resolution melting analysis using a LightScanner (Idaho Tech-
nology Inc, Salt Lake City, Utah, USA). PCRs were done for high
resolution melting analysis according to the manufacturer’s
instructions, using the primers 59-CCACCCAGCAAAGAAGG-39
and 59-CAGTGGGAAAGCACCAGA-39. Melting curve data were
acquired over a temperature range of 60e988C. The melting
curves obtained were analysed using the Small Amplicon Geno-
typing module of the LightScanner Analysis Software.
Allele specific PCR
The parental origin of mutations was determined by using allele
speciﬁc PCR (AS-PCR), also called the ampliﬁcation refractory
mutation system, to amplify and analyse the patient’s two
alleles separately.11 This method relies on the presence of a
heterozygous SNP in the same amplicon as the mutation.
AS-PCR was done for the SNPs listed in supplementary table
3 using the corresponding primers and speciﬁc ampliﬁcation
conditions. Products were ampliﬁed using recombinant Taq
DNA Polymerase (Invitrogen, Carlsbad, California, USA). Reac-
tions contained 13PCR buffer, 1.5 mM MgCl2, 200 mM of each
dNTP, 15 ng/ml of each primer, 0.5 U Taq DNA Polymerase, and
100 ng template DNA in a 20 ml reaction volume. PCRs were
cycled through 10 cycles of: denaturation at 948C for 30 s,
annealing for 30 s and extension at 728C, then 25 cycles of:
denaturation at 948C for 30 s, annealing 30 s and extension at
728C, followed by a ﬁnal extension at 728C for 10 min. Four sets
of reactions were done for each primer pair, using annealing
temperatures of 60, 62, 65 or 688C for the ﬁrst 10 PCR cycles and
55, 57, 60 or 638C for the subsequent 25 cycles. Extension times
varied according to the expected length of the PCR product and
these are listed in supplementary table 3. At least one homo-
zygous sample was included in all AS-PCRs as a control to
conﬁrm that ampliﬁcation was allele speciﬁc. If allele speciﬁcity
was not achieved at the annealing temperatures described above,
three further sets of reactions were done with annealing
temperatures of 688C followed by 638C, 708C followed by 658C,
and 728C followed by 678C. If no product was seen in the initial
PCRs, reactions were then done using lower annealing temper-
atures between 508C and 608C. AS-PCR products showing robust
ampliﬁcation and allele speciﬁcity were selected for sequencing.
These were puriﬁed using the Qiagen Qiaquick PCR puriﬁcation
kit (Qiagen, Hilden, Germany) and sequenced with BigDye v3.1
(Applied Biosystems Inc, Foster City, California, USA) using the
appropriate forward and reverse primers. Sequencing reactions
were analysed using an ABI 3730 capillary sequencer and traces
were examined for the presence of the patient’s mutation.
To summarise, patients and their parents were sequenced for
the exon in which their mutation was located, and adjacent
exons in cases where no informative SNPs were present in the
exon containing the mutation. Twenty-six SNPs, including four
not listed in dbSNP, were used for AS-PCR. Thirty-ﬁve different
primer combinations were used for AS-PCR; some SNPs were
used as the basis for multiple AS-PCRs. Details of the AS-PCRs
performed are listed in supplementary table 3.
The parental origin was determined for large deletions by
genotyping SNPs within the deletion. Non-transmission of a
genotype or haplotype from a parent to the affected child
indicated that the deletion originated in that parent’s allele.
Microsatellite analysis of informative families
All informative families were tested to conﬁrm family relation-
ships and gender of the parental samples using 12 highly poly-
morphic microsatellite markers. These were: D3S3680; D4S418;
D6S289; D7S2560; D8S281; D13S175; D13S221; D15S117;
D19S1150; DXS1113; DXS1036; DXS7423. PCRs were done
using the Qiagen Multiplex PCR kit according to the manu-
facturer’s instructions. The reverse primer of each pair was
labelled with either HEX or FAM. Products were analysed on an
ABI 3131 Genetic Analyzer.
RESULTS
The parental origin of the mutations was deﬁnitively deter-
mined for 44/91 unrelated patients; 43 with de novo mutations,
and one sibship (table 1: patient 44) of two sisters whose origi-
nating parent was thought to have gonadal mosaicism because
the same mutation was observed in both sisters and neither
parent. Thirty-three cases were of paternal origin and 11 of
maternal origin. The mutations, parental origins, ages of the
originating parents at birth and countries of origin for these 44
independent cases are listed in table 1. In an additional ﬁve cases
paternal DNA samples were not available (table 1: patients
45e49), and the mutations were shown not to originate from the
maternal allele. Thus, a paternal origin was presumed for these
mutations but it could not be deﬁnitely established that they
arose de novo. Although de novo origin from the paternal allele is
highly probable, given that these patients have DS and their
fathers were unaffected with no family history of epilepsy, these
patients were excluded from analyses of parental age and
mutation type. Microsatellite analysis of informative families
conﬁrmed family relationships and results for the X chromosome
markers indicated there had been no inadvertent switching of
paternal and maternal samples.
The 44 patients for whom parent-of-origin was determined
had 43 different mutations: one mutation recurred in two
unrelated patients (table 1: patients 31 and 32), one of whom had
paternal and the other maternal origin. The mutations seen in
these 44 patients included 33 nucleotide substitutions, seven
small (1e4 bp) deletions, one 7 bp insertion and three large
deletions. Of the nucleotide substitutions, 25 (74%) were paternal
and eight were maternal. Seven (88%) of the small deletions and
insertions were paternal while one was maternal. Two large
deletions were of maternal origin and one was paternal.
The largest subset of patients (25) were of Australian origin.
When the parental ages for the Australian families were
compared with the median parental ages from the general
Australian population for the years in which their children were
born (data collated from Australian Bureau of Statistics publi-
cations 3301.0, Births: Australia from 1998 to 2004), no signiﬁ-
cant difference in ages was seen (data not shown).
DISCUSSION
We were able to determine the parental origin of the mutation in
more than half of the patients we studied. It was necessary to
138 J Med Genet 2010;47:137e141. doi:10.1136/jmg.2008.065912
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assume de novo origin since a small percentage of gonadal
mosaicism is known in DS,27 28 which cannot be detected in the
absence of affected siblings. The determination of the parent-of-
origin of these putative de novo mutations relies on the presence
of a heterozygous SNP in the same amplicon as the mutation,
and also requires that it is possible to determine from which
parent each allele of the SNP was inherited. Therefore, it is not
possible to determine the parent-of-origin for every patient with
a de novo mutation. The proportion of patients for whom we
were able to determine the parent-of-origin was similar to that in
studies done for other genes using similar methods.11e15 19
De novo mutations in SCN1A arise most often, but not
exclusively, on the paternal chromosome. Of the 44 mutations
studied, 75% were paternally derived and 25% were maternally
derived. Similar proportions of small insertions and deletions
(88%) and nucleotide substitutions (74%) were paternally
derived. It is not possible to draw any deﬁnitive conclusions
about the parental origin of large deletions compared to other
Table 1 Details of patients for whom parent-of-origin was identified
Patient Phenotype Mutation Origin Parental age* Country of origin
1a Dravet c.41delT (p.F14fsX91) Maternal 33.5 Australia
2b Dravet c.111delC (p.P37fsX91) Paternal 28.2 Australia
3a Dravet c.251A/G (p.Y84C) Paternal 29.1 Canada
4a Dravet c.265-1G/A Paternal 32.4 New Zealand
5a Dravet c.302G/A (p.R101Q) Paternal 34.0 Canada
6a Dravet c.495-496-ins7 bp (p.T166fsX170) Paternal 28.4 Australia
7a Dravet c.512T/A (p.I171K) Paternal 24.1 New Zealand
8a Dravet c.523G/A (p.A175T) Paternal 45.3 UK
9a Dravet c.602þ1G/A Paternal 29.8 Australia
10a Dravet c.680T/G (p.I227S) Maternal 25.5 UK
11a Dravet c.1197C/A (p.Y339X) Paternal 32.1 Australia
12 DravetdMild c.1216G/T (p.V406F) Paternal 33.5 Australia
13a Dravet c.1237T/A (p.Y413N) Paternal 38.0 Canada
14a Dravet c.1662þ2T/C Paternal 38.3 Canada
15a SIMFE c.1724delT (p.F575fsX622) Paternal 32.7 Australia
16a Dravet c.2348T/C (p.L783P) Paternal 29.3 Canada
17a Dravet c.2562delA (p.G854fsX876) Paternal 41.9 Canada
18a Dravet c.2589þ3A/T Paternal 36.3 New Zealand
19a Dravet c.2831T/A (p.V994E) Paternal 32.5 Australia
20a Dravet c.2837G/A (p.R946H) Paternal 33.4 Australia
21a Dravet c.2849G/A (p.G950E) Paternal 39.0 Australia
22a CGE c.2946þ1G/T Paternal 35.8 Canada
23a Dravet c.3022G/T (p.E1008X) Maternal 24.4 Australia
24b Dravet c.3672þ1G/A Paternal 26.4 Australia
25 Dravet c.3968delC (p.P1323fsX1325) Paternal 41.2 Australia
26a Dravet c.4186T/G (p.C1396G) Maternal 22.1 Canada
27a Dravet c.4219C/T (p.R1407X) Paternal 29.8 Australia
28a Dravet c.4279C/T (p.Q1427X) Paternal 32.1 Australia
29b Dravet c.4339-14T/G Paternal 30.6 Australia
30 Dravet c.4348C/A (p.N1450K) Paternal 45.3 New Zealand
31a Dravet c.4547C/A (p.S1516X) Maternal 25.9 Australia
32 Dravet c.4547C/A (p.S1516X) Paternal 35.0 Australia
33 Dravet c.4558delC (p.G1520X) Paternal 26.0 UK
34a Dravet c.4633A/G (p.I1545V) Paternal 38.4 Australia
35a LGS c.4907G/A (p.R1636Q) Maternal 25.6 Australia
36a Dravet c.4934G/A (p.R1645Q) Maternal 26.6 Australia
37a CFE c.4970G/A (p.R1657H) Paternal 25.4 Australia
38a Dravet c.5176T/C (p.W1726R) Maternal 36.9 Canada
39a Dravet c.5347G/A (p.A1783T) Paternal 27.7 Australia
40a Dravet c.5536-5539delAAAC (p.K1846fsX1856) Paternal 38.4 Australia
41a Dravet c.5674C/T (p.R1892X) Maternal 37.9 UK
42c Dravet IVS20-IVS21del4,499bp Paternal 32.2 USA
43c Dravet Del exons 21e26 Maternal 30.4 Australia
44d Dravet Del exons 1e22 Maternal (known gonadal mosaicism) Israel
45a Dravet c.580G/A (p.D194N) Paternaly New Zealand
46a Dravet c.602þ5G/A Paternaly Australia
47a Dravet c.1811G/A (p.R604H) c.4573C/T
(p.R1525X)
Paternaly Australia
48a Dravet c.2833T/A (p.F945L) Paternaly Australia
49a Dravet c.3096delA (p.E1032fsX1045) Paternaly USA
*Parental age refers to age at birth of child, given in years to one decimal place.
yDNA for the patient’s father is unavailable, therefore it is not certain that these are de novo mutations. aOriginally described by Harkin et al3; boriginally described by Wallace et al25; coriginally
described by Mulley et al8; doriginally described by Marini et al.26
CFE, cryptogenic focal epilepsy; CGE, cryptogenic generalised epilepsy; LGS, LennoxeGastaut syndrome; SIMFE, severe infantile multifocal epilepsy.
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mutation types as only three patients with large deletions were
included in the study, and one of these was known to be the
result of gonadal mosaicism.
A bias towards paternal origin of de novo mutations is often,
but not always, observed in the genetic disorders for which
parent-of-origin has been studied.20 The proportion ranges from
exclusively paternal to an approximately equal frequency of
paternal and maternal origin. A preponderance of maternally
derived mutations has not been seen in any disorder caused by
point mutations or small insertions or deletions, although
maternal origin is seen more frequently for some large deletions
and chromosomal rearrangements (imprinted gene and parent-
of-origin effect database).20 The most extensively studied genes
with an exclusively paternal origin of mutations are the ﬁbro-
blast growth factor genes FGFR2 and FGFR3. Mutations in these
genes cause achondroplasia and several craniosynostosis
syndromes, and 79 of 79 de novo FGFR2 and 50 of 50 de novo
FGFR3 mutations studied were paternally derived.11e14 20 In
contrast, for the coagulation factor IX gene F9, 59 of 123
haemophilia B mutations studied were paternally derived, giving
an approximately equal distribution of the parent-of-origin for
this gene (imprinted gene and parent-of-origin effect database).20
The distribution of the parental origin of mutations in SCN1A
falls between these two extremes and is similar to those seen for
haemophilia A, Rett syndrome and neonatal diabetes.19 20
The greater frequency of paternally derived mutations in
SCN1A is likely to be due to the greater chance of mutations
occurring during spermatogenesis as compared to oogenesis. This
is due to the considerably higher number of mitoses that occur
during spermatogenesis compared to oogenesis. Twenty-two
mitoses followed by twomeioses occur during oogenesis, giving a
total of 23 chromosome replications. In contrast, the DNA in
sperm cells produced at the onset of puberty has already under-
gone 30 chromosome replications, with a further 23 replications
occurring each year.29 Therefore, sperm cells have a much higher
probability of having acquired mutations due to replication error,
compared with eggs at oogenesis.
It is also possible that some mutations of both paternal and
maternal origin are the result of somatic or gonadal mosaicism.
This has been described in sibships with SCN1A mutations27 28
and was observed in one of the families studied here (patient 44).
In these cases, themosaicismwas detected because of the presence
of the same mutation in siblings. By chance alone, however, not
all parents with somatic or gonadal mosaicism would have more
than one affected child and therefore these would not be detected.
The most commonly occurring of the six potential nucleotide
substitutions is a C:G/T:A transition. This substitution results
from the deamination either of cytosine to form uracil or of
5-methylcytosine to form thymine, followed by the incorpo-
ration of adenine into the complementary DNA strand during
the next replication. Methylated cytosines in CpG dinucleotides
are particularly susceptible to this form of mutagenesis. The
DNA in sperm cells is potentially more susceptible to this form of
mutation as it is more highly methylated than that in oocytes.30
Of the 33 nucleotide substitutions examined in this study with a
deﬁnite de novo origin, 14 (42%) were C:G/T:A substitutions
and 11 of these were paternally derived. This suggests that the
deamination of cytosine during spermatogenesis is a frequent
mutational mechanism causing de novo mutations in SCN1A.
The occurrence and relative frequencies of the paternally and
maternally derived mutations in SCN1A is similar to that seen in
several other genes including KCNJ11, another ion channel
gene.19 The mutations in both genes have been shown to result
from a mixture of replication errors during gametogenesis and
postzygotic mutations leading to gonadal mosaicism. This
contrasts with the exclusively paternal mutations seen in FGFR2
and FGFR3. The mutations in both these genes occur in ‘hot
spots’ at CpG dinucleotides and a pronounced paternal age effect
is seen, which may be due to selection for germ cells carrying
the mutation within the testis.29 This selection only occurs for
mutations in speciﬁc genes and does not appear to occur for
mutations in SCN1A.
This is the ﬁrst study of the parental origin of de novo
mutations in an epilepsy related gene. De novo SCN1A muta-
tions in DS and related epileptic encephalopathies confer
phenotypic effects through haploinsufﬁciency. They are most
frequently but not exclusively of paternal origin and are unre-
lated to parental age. Multiple mutational mechanisms are likely
to be involved in the occurrence of these mutations. Study of
further cases, especially those with large deletions or duplica-
tions, which may have a different proportion of paternal to
maternal origins, would be of interest to help understand how
this group of devastating epileptic encephalopathies arise. In
addition, the large number of de novo SCN1A mutations now
known in DS provide a useful model for the study of the
mechanisms contributing to different mutation types.
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